THERAPEUTIC TARGETING OF MDS & AML STEM CELLS WITH AN ANTISENSE INHIBITOR OF STAT3

被引：0
|
作者：
Shastri, A. [1 ]
Teixeira, M. [2 ]
Bhattacharya, S. [3 ]
Ramachandra, N. [3 ]
Lopez, R. [1 ]
Ravipati, G. [1 ]
Bhagat, T. [3 ]
Choudhary, G. [3 ]
Bartenstein, M. [3 ]
Gordon-Mitchell, S. [3 ]
Pradhan, K. [4 ]
Pellagatti, A. [5 ]
Boultwood, J. [6 ]
Kim, Y. [7 ]
Woessner, R. [8 ]
Will, B. [2 ]
Steidl, U. [2 ]
Verma, A. [1 ]
机构：
[1] Albert Einstein Coll Med, Hematooncol, New York, NY USA
[2] Albert Einstein Coll Med, Cell Biol, New York, NY USA
[3] Albert Einstein Coll Med, Mol Biol, New York, NY USA
[4] Albert Einstein Coll Med, Biostat, New York, NY USA
[5] Univ Oxford, Cell & Mol Biol, Oxford, England
[6] Univ Oxford, Mol Hematol, Oxford, England
[7] Ionis Biotech, San Diego, CA USA
[8] Astrazeneca, Boston, MA USA
来源：
LEUKEMIA RESEARCH | 2017年 / 55卷
关键词：
D O I：
10.1016/S0145-2126(17)30128-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15
引用
收藏
页码：S8 / S8
页数：1
相关论文
共 50 条
  • [1] Targeting of MDS and AML Stem Cells Via Inhibition of STAT3 By Pyrimethamine
    Shastri, Aditi
    Schinke, Carolina
    Yanovsky, Asya Varshavsky
    Bhagat, Tushar D.
    Giricz, Orsolya
    Barreyro, Laura
    Boultwood, Jacqueline
    Pellagati, Andrea
    Yu, Yiting
    Brown, Jennifer R.
    Frank, David A.
    Das, Bhaskar
    Kambhampati, Suman
    Will, Britta
    Steidl, Ulrich
    Verma, Amit
    BLOOD, 2014, 124 (21)
  • [2] Targeting MDS and AML Stem Cells with AZD-9150 Mediated Inhibition of STAT3
    Shastri, Aditi
    Teixeira, Margarida
    Bhattacharyya, Sanchari
    Ramachandra, Nandini
    Lopez, Robert
    Ravipati, Goutham
    Feld, Jonathan
    Dhar, Yosman
    Bhagat, Tushar Damodar
    Choudhary, Gaurav
    Giricz, Orsolya
    Bartenstein, Matthias
    Sridharan, Ashwin
    Gordon-Mitchell, Shanisha
    Nawanko, George
    Pradhan, Kith
    Ahmed, Amal
    Raghavendran, Keshav
    Kanna, Rubashruti
    Khan, Hina
    Mantzaris, Ioannis
    Pellagatti, Andrea
    Boultwood, Jacqueline
    Kim, Youngsoo
    McLeod, Robert
    Woessner, Richard
    Steidl, Ulrich
    Will, Britta
    Verma, Amit
    BLOOD, 2016, 128 (22)
  • [3] Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells
    Shastri, Aditi
    Choudhary, Gaurav
    Teixeira, Margarida
    Gordon-Mitchell, Shanisha
    Ramachandra, Nandini
    Bernard, Lumie
    Bhattacharyya, Sanchari
    Lopez, Robert
    Pradhan, Kith
    Giricz, Orsolya
    Ravipati, Goutham
    Wong, Li-Fan
    Cole, Sally
    Bhagat, Tushar D.
    Feld, Jonathan
    Dhar, Yosman
    Bartenstein, Matthias
    Thiruthuvanathan, Victor J.
    Wickrema, Amittha
    Ye, B. Hilda
    Frank, David A.
    Pellagatti, Andrea
    Boultwood, Jacqueline
    Zhou, Tianyuan
    Kim, Youngsoo
    MacLeod, Robert
    Epling-Burnette, P. K.
    Ye, Minwei
    McCoon, Patricia
    Woessner, Richard
    Steidl, Ulrich
    Will, Britta
    Verma, Amit
    JOURNAL OF CLINICAL INVESTIGATION, 2018, 128 (12): : 5479 - 5488
  • [4] Distinct Role of STAT3 and STAT5 Factors in MDS and AML
    Fasouli, Eirini Sofia
    Giavi, Konstantina
    Makri, Charikleia
    Bystrykh, Leonid
    Bouchla, Anthi
    Athanasiadis, Emmanouil
    Vatsellas, Giannis
    Pappa, Vasiliki
    Katsantoni, Eleni
    BLOOD, 2023, 142
  • [5] Pyrimethamine, a STAT3 Inhibitor, Synergizes with Venetoclax and Shows Efficacy in Hypomethylating Agent Resistant MDS and AML
    Rivera, Bianca L.
    Chakraborty, Samarpana
    Shi, Yang
    Zhang, Hui
    Choudhary, Gaurav S.
    Gordon, Shanisha
    Pradhan, Kith
    Fu, Bowen
    Tosic, Isidora
    Zhao, Rongbao
    Goldfinger, Mendel
    Mantzaris, Ioannis
    Carbajal, Milagros
    Ramachandra, Nandini
    Konopleva, Marina
    Frank, David
    Saunthararajah, Yogenthiran
    Verma, Amit
    Shastri, Aditi
    BLOOD, 2022, 140 : 6892 - 6893
  • [6] PYRIMETHAMINE, A STAT3 INHIBITOR, HAS SYNERGY WITH VENETOCLAX AND IS EFFICACIOUS IN HYPOMETHYLATING AGENT RESISTANT MDS/AML
    Shastri, A.
    Zhang, H.
    Rivera-Pena, B.
    Chakraborty, S.
    LEUKEMIA RESEARCH, 2023, 128
  • [7] Therapeutic targeting of STAT3 in nasopharyngeal carcinoma
    Hui, Shinyee
    Lo, Kwok Wai
    Liu, Alyssa Ming-Ting
    Law, Marcus Hung-Nam
    Ng, Linda Wing-Chi
    Li, Peter Tin-Chung
    Cheung, Siu Tim
    CANCER RESEARCH, 2020, 80 (16)
  • [8] Chidamide, a novel histone deacetylase inhibitor, inhibits the viability of MDS and AML cells by suppressing JAK2/STAT3 signaling
    Zhao, Sida
    Guo, Juan
    Zhao, Youshan
    Fei, Chengming
    Zheng, Qingqing
    Li, Xiao
    Chang, Chunkang
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2016, 8 (07): : 3169 - 3178
  • [9] Therapeutic targeting of STAT3 with small interference RNAs and antisense oligonucleotides embedded exosomes in liver fibrosis
    Tang, Min
    Chen, Yang
    Li, Bingrui
    Sugimoto, Hikaru
    Yang, Sujuan
    Yang, Changqing
    LeBleu, Valerie S.
    McAndrews, Kathleen M.
    Kalluri, Raghu
    FASEB JOURNAL, 2021, 35 (05):
  • [10] Targeting the prostate cancer stem cell niche with the STAT3 inhibitor galiellalactone.
    Canesin, Giacomo
    Collins, Anne T.
    Hellsten, Rebecka
    Maitland, Norman J.
    Bjartell, Anders
    CANCER RESEARCH, 2018, 78 (16) : 45 - 46
12345